This is a Phase I, single centre, randomised, double-blind, placebo-controlled, parallel group study to assess the safety, tolerability and pharmacokinetics of AZD2423 following single ascending dose administration to healthy Japanese subjects.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
QUADRUPLE
Enrollment
32
Research Site
Croydon, United Kingdom
Research Site
London, United Kingdom
To asses the safety: Adverse events, vital signs, electrocardiograms (ECGs), laboratory variables.
Time frame: From screening period to follow-up visit, 40 days (Maximum).
To characterize the pharmacokinetics of AZD2423 in plasma and urine.
Time frame: Blood and urine sampling from pre-dose until follow-up visit, 10 days (approximately)
Exploratory endpoints;Levels of CCL2 pre-and post dose
Time frame: Blood sampling after dosing, 3 days
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.